Business Wire

SEOUL-SEMICONDUCTOR

Share
Seoul Semiconductor SunLike Series Natural Spectrum LEDs Promote Human Visual Comfort, Daytime Alertness, Mood and Sleep Intensity According to on a Recent Scientific Study

Seoul Semiconductor Co., Ltd. (KOSDAQ:046890), a leading global innovator of LED products and technology, announced that its SunLike Series natural spectrum LEDs have been identified as a key light source for promoting human well-being, based on the results of a recent comprehensive sleep study conducted by scientists at the University of Basel.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190516005262/en/

Seoul Semiconductor developed SunLike Series natural spectrum LEDs in collaboration with Toshiba Materials’ TRI-R spectrum technology in 2017 as the first LED light source to closely match the spectrum of natural sunlight. The two companies have since promoted this natural sunlight spectrum technology through its favorable effects on human well-being and sleep as a key value in the evolution of lighting.

There has been an increase in research activity on the relationship between light and human bio-function, including a recent scientific study focusing on the effects of light spectrum on sleep quality, visual comfort, well-being and daytime alertness conducted by Prof. Christian Cajochen and his team at the University of Basel in Switzerland, entitled: “Effect of Daylight LED on Visual Comfort, Melatonin, Mood, Waking Performance, and Sleep,” published in the Journal of Lighting and Research Technology published on March 24, 2019.

It is well established that light is one of the strongest control factors for human circadian rhythms, such as the secretion of the sleep promoting hormone melatonin. Thus, optimal lighting condition during daytime are crucial to prevent circadian rhythm disturbances which can lead to sleep disorders and other life-style related diseases. Over the past ten years, there have been related scientific studies in the fields of sleep, chronobiology, physiology, as well as the impact of light quality in elderly care.

According to Prof. Cajochen’s research, LED light sources with the same measured correlated color temperature (CCT) and intensity, but different spectral output, can have different effects on human behavior and physiology. LED light sources with a spectrum close to natural sunlight produced better visual comfort, more alertness, and happier moods in the morning and evening among the test participants, compared to those exposed to conventional spectrum LEDs. The research tested subjects’ visual comfort, circadian physiology, daytime alertness, mood, cognitive performance, and sleep after being exposed to both conventional LED light, and natural spectrum LED light for 49 hours in a laboratory setting.

Quoting from the paper: “We have evidence that a daylight [natural spectrum] LED solution has beneficial effects on visual comfort, daytime alertness, mood, and sleep intensity in healthy volunteers. Delta EEG activity (0.75–4.5Hz) was significantly higher after daylight-LED than conventional-LED exposure during the post-light exposure night.” [NOTE: Delta EEG (electroencephalogram) measurements record delta waves, the brain waves associated with Stage 3 non-rapid eye movement (NREM) sleep, or “slow-wave sleep” (SWS), and aid in characterizing the depth of sleep.]

By providing the same spectrum as sunlight and in the visible light range, SunLike Series natural spectrum LEDs deliver benefits to human well-being, consistent with the mechanisms of vision that impact both image forming and non-image forming aspects of the eye, as well as the control of circadian rhythms. While the qualities of artificial light have been described primarily with color and intensity thus far, SunLike Series natural spectrum LEDs have introduced light spectrum as another important factor in determining overall light quality.

“This research conducted by the University of Basel suggests another important aspect to the evolving direction of artificial light over the past eighty years. In addition to the properties of energy efficiency and long life, we have added the factor of ‘human well-being’ to modern LED light sources,” said Nam Ki-bum, sales executive vice-president of Seoul Semiconductor. “As the world’s first mass-produced LED devices to achieve natural sunlight quality, SunLike Series LEDs are advancing lighting technology in this important area as we continue to respond to market needs from our customers’ lighting applications.”

Contact:

Seoul Semiconductor Inc. North America Andrew Smith Tel: +1 (901) 831-6614 Email: andrew.smith@seoulsemicon.com

Asia and Europe Jeong-hee Kim Tel: +82-70-4391-8311 Email: jeonghee.kim@seoulsemicon.com

Link:

ClickThru

Social Media:

https://www.facebook.com/seoulsemiconductorglobal

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release

Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On

Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release

52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society

Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release

- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and

Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 12:31:00 CET | Press release

The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p

Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 00:49:00 CET | Press release

‒ Named Most Respected Public Semiconductor Company Achieving $100 Million to $500 Million in Annual Sales ‒ Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye